FI943564L - Uusia polypeptidejä, joilla on jyvässolupesäkkeitä stimuloivaa aktiivisuutta, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksia - Google Patents

Uusia polypeptidejä, joilla on jyvässolupesäkkeitä stimuloivaa aktiivisuutta, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksia Download PDF

Info

Publication number
FI943564L
FI943564L FI943564A FI943564A FI943564L FI 943564 L FI943564 L FI 943564L FI 943564 A FI943564 A FI 943564A FI 943564 A FI943564 A FI 943564A FI 943564 L FI943564 L FI 943564L
Authority
FI
Finland
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
granulocyte colony
stimulating activity
Prior art date
Application number
FI943564A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI943564A7 (fi
FI943564A0 (fi
Inventor
Patrice Yeh
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of FI943564A7 publication Critical patent/FI943564A7/fi
Publication of FI943564A0 publication Critical patent/FI943564A0/fi
Publication of FI943564L publication Critical patent/FI943564L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI943564A 1992-01-31 1993-01-28 Uusia polypeptidejä, joilla on jyvässolupesäkkeitä stimuloivaa aktiivisuutta, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksia FI943564L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9201065A FR2686900B1 (fr) 1992-01-31 1992-01-31 Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
PCT/FR1993/000086 WO1993015211A1 (fr) 1992-01-31 1993-01-28 Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant

Publications (3)

Publication Number Publication Date
FI943564A7 FI943564A7 (fi) 1994-07-29
FI943564A0 FI943564A0 (fi) 1994-07-29
FI943564L true FI943564L (fi) 1994-07-29

Family

ID=9426191

Family Applications (1)

Application Number Title Priority Date Filing Date
FI943564A FI943564L (fi) 1992-01-31 1993-01-28 Uusia polypeptidejä, joilla on jyvässolupesäkkeitä stimuloivaa aktiivisuutta, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksia

Country Status (8)

Country Link
US (1) US5665863A (cg-RX-API-DMAC7.html)
EP (1) EP0624200A1 (cg-RX-API-DMAC7.html)
JP (1) JPH07503844A (cg-RX-API-DMAC7.html)
CA (1) CA2125979A1 (cg-RX-API-DMAC7.html)
FI (1) FI943564L (cg-RX-API-DMAC7.html)
FR (1) FR2686900B1 (cg-RX-API-DMAC7.html)
NO (1) NO942858L (cg-RX-API-DMAC7.html)
WO (1) WO1993015211A1 (cg-RX-API-DMAC7.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
FR2719593B1 (fr) * 1994-05-06 1996-05-31 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur préparation et composition pharmaceutique les contenant.
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
TWI242563B (en) * 1998-04-30 2005-11-01 Tanox Inc Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor
CN101070344A (zh) * 1998-04-30 2007-11-14 泰诺士公司 G－csf受体兴奋剂抗体及其筛选方法
AU773428B2 (en) * 1998-10-13 2004-05-27 Peptide Biosciences, Inc. Stabilized bioactive peptides and methods of identification, synthesis and use
US20030190740A1 (en) 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
TR200401573T4 (tr) 2000-02-29 2004-08-23 Pfizer Products Inc. Stabilize edilmiş granülosit koloni uyarıcı faktör
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
EP1803730A1 (en) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
ATE406384T1 (de) * 2000-12-07 2008-09-15 Lilly Co Eli Glp-1 fusion proteine
US20050244931A1 (en) * 2001-04-12 2005-11-03 Human Genome Sciences, Inc. Albumin fusion proteins
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20060084794A1 (en) * 2001-04-12 2006-04-20 Human Genome Sciences, Inc. Albumin fusion proteins
US20050054051A1 (en) * 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003030821A2 (en) * 2001-10-05 2003-04-17 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
WO2003076567A2 (en) * 2002-03-05 2003-09-18 Eli Lilly And Company Heterologous g-csf fusion proteins
US7423007B2 (en) 2002-08-27 2008-09-09 Biokine Therapeutics Ltd. Cxcr4 antagonist and use thereof
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
WO2005034877A2 (en) * 2003-10-10 2005-04-21 University Of Southern California G-csf transferrin fusion proteins
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
EP1729795B1 (en) * 2004-02-09 2016-02-03 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005121174A2 (en) * 2004-06-04 2005-12-22 Five Prime Therapeutics, Inc. Novel g-csf polypeptides, polynucleotides, modulators thereof, and methods of use
IL164942A0 (en) * 2004-10-31 2005-12-18 Yeda Res & Dev The use of a protease or a protease inhibitor for the manufacture of medicaments
AU2005306894B2 (en) 2004-11-05 2011-11-24 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
WO2008075370A2 (en) 2006-12-21 2008-06-26 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy
NZ600382A (en) 2008-07-23 2013-11-29 Ambrx Inc Modified bovine G-CSF polypeptides and their uses
WO2010083434A2 (en) 2009-01-16 2010-07-22 Teva Biopharmaceuticals Usa, Inc. New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor
WO2010092571A2 (en) 2009-02-11 2010-08-19 Yeda Research And Development Co. Ltd. Short beta-defensin-derived peptides
US9427456B2 (en) 2009-06-14 2016-08-30 Biokine Therapeutics Ltd. Peptide therapy for increasing platelet levels
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
AU2012289433B2 (en) 2011-07-25 2017-07-27 Evive Biotechnology (Shanghai) Ltd Use of G-CSF dimer in preparation of medicament for treatment of neurodegenerative diseases
WO2013160895A1 (en) 2012-04-24 2013-10-31 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
US20140271538A1 (en) 2013-03-15 2014-09-18 Teva Pharmaceutical Industries Ltd. Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor for the Prevention of Neutropenia in Pediatric Patients
GB201316592D0 (en) * 2013-09-18 2013-10-30 Levicept Ltd Fusion protein
GB201412748D0 (en) * 2014-07-17 2014-09-03 Levicept Ltd Therapeutic use of P75NTR neurotrophin binding protein
CN107921087A (zh) 2015-07-16 2018-04-17 百欧肯治疗有限公司 治疗癌症的组合物及方法
EP3348635B1 (en) 2015-09-08 2021-02-17 JCR Pharmaceuticals CO., LTD. Novel human serum albumin mutant
EP3419645B1 (en) 2016-02-23 2020-09-02 BioLineRx Ltd. Method of selecting a treatment regimen in acute myeloid leukemia (aml)
JP2017165713A (ja) 2016-03-14 2017-09-21 Ｊｃｒファーマ株式会社 血清アルブミン−２０ｋ成長ホルモン融合タンパク質
US10866963B2 (en) 2017-12-28 2020-12-15 Dropbox, Inc. File system authentication

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR871067B (en) * 1986-07-18 1987-11-19 Chugai Pharmaceutical Co Ltd Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
FR2649991B2 (fr) * 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5298243A (en) * 1988-10-20 1994-03-29 Denki Kagaku Kogyo Kabushiki Kaisha Colony stimulating factor-gelatin conjugate
JP2989002B2 (ja) * 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
EP0395918A3 (en) * 1989-04-13 1991-10-23 Vascular Laboratory, Inc. Plasminogen activator complex of pure pro-urokinase covalently bound by a disulfide bridge to human serum albumin
GB8909916D0 (en) * 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
EP0489116B1 (en) * 1989-08-22 1994-04-06 Immunex Corporation Fusion proteins comprising gm-csf and il-3

Also Published As

Publication number Publication date
FI943564A7 (fi) 1994-07-29
FI943564A0 (fi) 1994-07-29
NO942858D0 (cg-RX-API-DMAC7.html) 1994-08-01
FR2686900A1 (fr) 1993-08-06
EP0624200A1 (fr) 1994-11-17
US5665863A (en) 1997-09-09
NO942858L (no) 1994-08-01
FR2686900B1 (fr) 1995-07-21
CA2125979A1 (fr) 1993-08-05
WO1993015211A1 (fr) 1993-08-05
JPH07503844A (ja) 1995-04-27

Similar Documents

Publication Publication Date Title
FI943564L (fi) Uusia polypeptidejä, joilla on jyvässolupesäkkeitä stimuloivaa aktiivisuutta, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksia
FI20010334L (fi) Granulosyyttipesäkkeitä stimuloivia polypeptidejä, niitä sisältävä farmaseuttinen koostumus, ja niiden lääketieteellinen käyttö
FI943565L (fi) Uusia veren hyytymistä estäviä polypeptidejä, niiden valmistus ja niitä sisältävä farmaseuttinen koostumus
FI943563L (fi) Uusia biologisesti aktiivisia polypeptidejä, niiden valmistus ja niitä sisältävä farmaseuttinen koostumus
NZ218089A (en) 7-piperazinyl, 4-oxoquinolines and pharmaceutical compositions
IT1232677B (it) Composizione farmaceutica contenente ranitidina
FI844289A7 (fi) Uusia polypeptidejä, joilla on -amylaasi-estävä vaikutus, niiden käyttö ja farmaseuttiset valmistee
IL77294A (en) 2-piperazino-4,7-di(cyclo)amino piperidine derivatives,their preparation and pharmaceutical compositions containing them
ZA89792B (en) Pharmaceutical compositions with improved stability
IL71951A0 (en) Polypeptides having interferon activity,their preparation and pharmaceutical compositions containing them
FI893643A0 (fi) Farmaceutiska kompositioner.
DE3682083D1 (de) Pharmazeutische zusammensetzungen.
DE3579730D1 (de) Eisen-3-hydroxypyron- oder 3-hydroxypyridon-komplexe und diese enthaltende pharmazeutische zusammensetzungen.
FI943645L (fi) Uusia bakkatiini-III ja 10-deasetyylibakkatiini-III-johdannaisia, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksia
DE3583765D1 (de) Hydantoinderivate und diese enthaltende pharmazeutische zusammensetzungen.
NZ217123A (en) 7-alpha-cephalosporins, pharmaceutical compositions and intermediate compounds
IL92830A0 (en) Capsaicin derivatives,their preparation and pharmaceutical compositions containing them
DE3674040D1 (de) Pharmazeutische zusammensetzungen.
IT1213453B (it) Composizione farmaceutica.
IT8621393A0 (it) Composizioni farmaceutiche ad azione vasodilatatrice e dantianossica.
IL79469A0 (en) Substituted benzamides,their preparation and pharmaceutical compositions containing them
HUT70031A (en) Alfa, omega-diarylalkane derivatives, their preparation and pharmaceutical compositions containing them
IL78432A (en) Dichloroaniline derivatives,their preparation and pharmaceutical compositions containing them
IL99009A0 (en) Polypeptides,their preparation and pharmaceutical compositions containing them
NZ217248A (en) Gem-dihalo-1,8-diamino-4-aza-octones and pharmaceutical compositions

Legal Events

Date Code Title Description
FD Application lapsed